StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) shareholders

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
89.5%
27M of 31M shares
Institutional holders
176
24 new, 30 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 220 sales
Net sold $19.13M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
RTW Investments, LP
Joint filing with Roderick Wong (9.30%)
2,758,3359.30%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.2,338,0058.20%13G (passive) amendmentMar 31, 2025
Roderick Wong
Joint filing with RTW Investments, LP (7.20%)
2,115,2377.20%13G (passive)Dec 31, 2025
Principal Global Investors, LLC1,585,6395.89%13G (passive)Dec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CSTLValueChange% of portfolio
BlackRock, Inc.3,291,96310.78%$78.51M+309,0170.00%
Rtw Investments, LP2,778,3359.09%$66.26M+20,0000.57%
Principal Financial Group Inc1,726,6485.65%$41.18M−43,2290.02%
Vanguard Capital Management LLC1,226,4974.01%$29.25M+48,9750.00%
Acadian Asset Management LLC918,6683.01%$21.90M+434,2270.03%
Vanguard Portfolio Management LLC840,7852.75%$20.05M−20,9860.00%
Summit Partners Public Asset Management, LLC824,8722.70%$19.67M−115,8130.35%
State Street Corp822,0792.69%$19.63M+53,0000.00%
Allianz Asset Management GmbH811,3242.66%$19.92M–0.02%
Geode Capital Management, LLC795,9122.61%$18.99M+67,8120.00%
Mackenzie Financial Corp793,5072.60%$18.93M+719,3960.02%
Dimensional Fund Advisors LP791,0852.59%$18.87M−248,6760.00%
Jefferies Financial Group Inc.647,3912.12%$15.44MNew0.10%
Qube Research & Technologies Ltd589,3001.93%$14.05M+29,7170.01%
AIGH Capital Management LLC545,1011.78%$13.00M−45,5000.82%
Renaissance Technologies LLC371,2001.22%$8.85M−161,6000.01%
Goldman Sachs Group Inc358,3971.17%$8.55M+17,2260.00%
Point72 Asset Management, L.P.357,3171.17%$8.52MNew0.01%
Kennedy Capital Management LLC348,3711.14%$8.31MNew0.15%
Connor, Clark & Lunn Investment Management Ltd.331,7271.09%$7.91M−45,3550.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202617627M89.5%24 / 7956 / 305M5M
Q1 202618628M90.4%29 / 7261 / 366M3M
Q4 202519527M89.5%43 / 6568 / 175M4M
Q3 202517327M87.3%37 / 6253 / 153M3M
Q2 202515227M86.9%16 / 6945 / 424M4M
Q1 202518026M84.9%30 / 7456 / 446M6M
Q4 202419727M87.2%40 / 6666 / 275M4M
Q3 202418526M84.9%43 / 7547 / 167M3M
Q2 202415925M82.8%32 / 5450 / 233M4M
Q1 202415126M86.3%18 / 5455 / 174M2M
Q4 202315324M79.9%37 / 5644 / 184M2M
Q3 202313523M75.8%22 / 5241 / 163M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

223 funds held CSTL in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CSTLValue% of fundAs of
Vanguard Total Stock Market Index Fund852,7042.79%$20.34M0.00%Jun 30, 2026
iShares Russell 2000 ETF781,3672.56%$18.64M0.02%Jun 30, 2026
SmallCap Fund725,1382.37%$20.30M0.97%Jul 31, 2026
Vanguard Extended Market Index Fund342,6551.12%$8.17M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund327,8061.07%$9.18M0.03%Jul 31, 2026
Strategic Advisers U.S. Total Stock Fund312,0661.02%$6.58M0.01%May 31, 2026
iShares Russell 2000 Value ETF278,6850.91%$6.65M0.05%Jun 30, 2026
Wasatch Micro Cap Fund276,6850.91%$6.60M0.98%Jun 30, 2026
Vanguard Explorer Fund275,8910.90%$7.72M0.03%Jul 31, 2026
Buffalo Small Cap Growth Fund239,6140.78%$5.71M1.22%Jun 30, 2026
iShares Biotechnology ETF208,2670.68%$4.97M0.05%Jun 30, 2026
Vanguard Strategic Small-Cap Equity Fund179,3260.59%$4.28M0.14%Jun 30, 2026
Fidelity Extended Market Index Fund151,7000.50%$3.20M0.01%May 31, 2026
BlackRock Advantage Small Cap Core Fund151,5720.50%$3.20M0.06%May 29, 2026
Vanguard Russell 2000 Index Fund147,7660.48%$3.11M0.02%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Derek J. MaetzoldPres. & Chief Exec. Officer, Director155,9420.51%Nov 4, 2026
Tobin W. JuvenalChief Commercial Officer34,9670.11%Nov 13, 2026
Kristen M. OelschlagerChief Operating Officer86,0050.28%Oct 5, 2026
Frank StokesChief Financial Officer35,1770.12%Aug 18, 2026
Ellen GoldbergDirector40,9210.13%Jun 1, 2026
Kim CapleDirector36,1210.12%Jun 1, 2026
G. Bradley ColeDirector32,9760.11%Jun 1, 2026
Rodney CottonDirector32,9980.11%Jun 1, 2026
Daniel BradburyDirector35,6310.12%Jun 1, 2026
Miles HarrisonDirector35,6310.12%Jun 1, 2026
Tiffany OlsonDirector39,5730.13%Jun 1, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Tobin W. Juvenal
Chief Commercial Officer
Nov 11, 2026Sale−3,195$35.07$112.05K32,737
Tobin W. Juvenal
Chief Commercial Officer
Nov 11, 2026Option exercise+3,195$29.50$94.25K35,932
Tobin W. Juvenal
Chief Commercial Officer
Nov 11, 2026Sale(10b5-1 plan)−2,828$35.04$99.10K32,737
Tobin W. Juvenal
Chief Commercial Officer
Nov 9, 2026Sale(10b5-1 plan)−3,288$32.67$107.42K35,565
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−325$36.81$11.96K1,396
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−382$36.81$14.06K1,642
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−1,025$36.81$37.73K3,904
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−2,393$36.01$86.16K1,721
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−2,816$36.01$101.39K2,024
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Nov 2, 2026Sale(10b5-1 plan)−7,555$36.01$272.02K4,929
Tobin W. Juvenal
Chief Commercial Officer
Oct 28, 2026Sale(10b5-1 plan)−5,341$36.62$195.58K38,853
Tobin W. Juvenal
Chief Commercial Officer
Oct 28, 2026Sale(10b5-1 plan)−1,237$35.58$44.01K44,194
Tobin W. Juvenal
Chief Commercial Officer
Oct 26, 2026Sale(10b5-1 plan)−3,288$33.08$108.77K45,431
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 19, 2026Sale(10b5-1 plan)−2,718$31.91$86.73K4,114
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 19, 2026Sale(10b5-1 plan)−3,198$31.91$102.05K4,840
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 19, 2026Sale(10b5-1 plan)−8,580$31.91$273.79K12,484
Tobin W. Juvenal
Chief Commercial Officer
Oct 12, 2026Sale(10b5-1 plan)−3,288$33.64$110.61K48,719
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 5, 2026Sale(10b5-1 plan)−2,718$35.57$96.67K6,832
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 5, 2026Sale(10b5-1 plan)−3,198$35.57$113.74K8,038
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 5, 2026Sale(10b5-1 plan)−8,580$35.57$305.16K21,064
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Oct 5, 2026Option exercise+8,165$2.39$19.51K29,644
Kristen M. Oelschlager
Chief Operating Officer
Oct 1, 2026Sale(10b5-1 plan)−1,346$36.38$48.97K13,356
Kristen M. Oelschlager
Chief Operating Officer
Oct 1, 2026Sale(10b5-1 plan)−2,807$35.75$100.35K14,702
Kristen M. Oelschlager
Chief Operating Officer
Oct 1, 2026Option exercise+4,153$3.38$14.04K17,509
Tobin W. Juvenal
Chief Commercial Officer
Sep 30, 2026Sale(10b5-1 plan)−1,034$34.20$35.36K52,007
Tobin W. Juvenal
Chief Commercial Officer
Sep 29, 2026Sale(10b5-1 plan)−5,543$35.50$196.77K53,041
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 21, 2026Sale(10b5-1 plan)−8,580$35.33$303.13K21,479
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 21, 2026Option exercise+8,580$2.39$20.51K30,059
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 21, 2026Sale(10b5-1 plan)−3,198$35.33$112.99K11,236
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 21, 2026Sale(10b5-1 plan)−2,718$35.33$96.03K9,550
Tobin W. Juvenal
Chief Commercial Officer
Sep 15, 2026Sale(10b5-1 plan)−3,294$35.14$115.75K58,584
Tobin W. Juvenal
Chief Commercial Officer
Sep 14, 2026Sale(10b5-1 plan)−3,306$32.32$106.85K61,878
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−223$32.78$7.31K21,479
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−83$32.78$2.72K14,434
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−71$32.78$2.33K12,268
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−2,656$32.00$84.99K12,339
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−3,124$32.00$99.97K14,517
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Sale(10b5-1 plan)−8,361$32.00$267.55K21,702
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Sep 11, 2026Option exercise+8,584$2.39$20.52K30,063
Kristen M. Oelschlager
Chief Operating Officer
Sep 1, 2026Option exercise+4,152$3.38$14.03K17,508
Kristen M. Oelschlager
Chief Operating Officer
Sep 1, 2026Sale(10b5-1 plan)−3,952$33.36$131.84K13,556
Kristen M. Oelschlager
Chief Operating Officer
Sep 1, 2026Sale(10b5-1 plan)−200$34.02$6.80K13,356
Tobin W. Juvenal
Chief Commercial Officer
Aug 31, 2026Sale(10b5-1 plan)−1,730$32.81$56.76K65,184
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−257$33.14$8.52K11,277
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Option exercise+12,428$2.39$29.70K33,907
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−11,472$33.14$380.18K22,435
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−21$33.88$71111,256
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−21$33.88$71111,256
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−21$33.88$71111,256
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−177$33.88$6.00K14,995
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−209$33.88$7.08K17,641
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−956$33.88$32.39K21,479
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−257$33.14$8.52K11,277
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−21$33.88$71111,256
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−257$33.14$8.52K11,277
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−257$33.14$8.52K11,277
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−2,129$33.14$70.56K15,172
Derek J. Maetzold
Pres. & Chief Exec. Officer, Director
Aug 28, 2026Sale(10b5-1 plan)−2,505$33.14$83.02K17,850
Tobin W. Juvenal
Chief Commercial Officer
Aug 25, 2026Sale(10b5-1 plan)−9,050$35.04$317.11K66,914
Kristen M. Oelschlager
Chief Operating Officer
Aug 25, 2026Sale−5,223$34.64$180.92K72,649

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.03%
2M shares short
Days to cover
6.1
At 0M shares a day
Change since last report
+4.6%
From 2M shares
Short volume, 20 days
47.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Castle Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,667 shares on Aug 20, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Tobin W. Juvenal
Chief Commercial Officer
Nov 9, 202613,154$452.23KNov 9, 2026Acquired as compensation -- Restricted Stock Units
Derek J. Maetzold
Officer
Nov 2, 202621,438$749.04KNov 2, 2026Acquired as a gift
Tobin W. Juvenal
Chief Commercial Officer
Oct 13, 202613,154$430.93KOct 12, 2026Acquired as compensation -- Restricted Stock Units
Derek J. Maetzold
Officer
Oct 5, 202628,992$1.06MOct 5, 2026Acquired as a gift
Kristen M. Oelschlager
Officer
Oct 1, 20264,153$147.56KOct 1, 2026Exercise of Stock Options
Tobin W. Juvenal
Chief Commercial Officer
Sep 14, 202613,177$440.64KSep 14, 2026Acquired as compensation -- Restricted Stock Units
Derek J. Maetzold
Officer
Sep 11, 202629,014$938.02KSep 11, 2026Acquired as a gift
Tobin W. Juvenal
Chief Commercial Officer
Aug 25, 202622,500$787.50KAug 25, 2026Acquired as compensation -- Restricted Stock Units
Kristen M. Oelschlager
Officer
Aug 24, 202624,602$841.39KAug 24, 2026Retitled existing joint account into trust name
Franklin M. Stokes
Officer
Aug 14, 202624,908$741.49KAug 14, 2026Restricted Stock
Derek J. Maetzold
Officer
Aug 14, 202625,792$763.96KAug 14, 2026Acquired as gift
Tobin W. Juvenal
Chief Commercial Officer
Jul 31, 202622,500$630.00KJul 31, 2026Acquired as compensation -- Restricted Stock Units
Derek J. Maetzold
Officer
Jul 31, 202667,662$1.89MJul 31, 2026Acquired as gift
Derek J. Maetzold
Officer
Jul 1, 202623,844$589.19KJul 1, 2026Acquired as gift
Kristen M. Oelschlager
Officer
Jun 16, 202629,911$617.96KJun 16, 2026Exercise of Stock Options

Congress trades

1 trade in Castle Biosciences reported by 1 member of the House

MemberTypeTradedAmountFiled
Josh Gottheimer
NJ05 · joint account
Sold (part)Mar 15, 2022$1K–15KApr 17, 2022

See a number that looks wrong?